- Home
- AMIX vs KLTO Comparison
AMIX vs KLTO Comparison
Compare AMIX & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- KLTO
- Stock Information
- Founded
- AMIX 2014
- KLTO 2019
- Country
- AMIX United States
- KLTO United States
- Employees
- AMIX N/A
- KLTO N/A
- Industry
- AMIX
- KLTO
- Sector
- AMIX
- KLTO
- Exchange
- AMIX NYSE
- KLTO NYSE
- Market Cap
- AMIX 5.5M
- KLTO 5.0M
- IPO Year
- AMIX N/A
- KLTO N/A
- Fundamental
- Price
- AMIX $1.97
- KLTO $0.16
- Analyst Decision
- AMIX
- KLTO
- Analyst Count
- AMIX 0
- KLTO 0
- Target Price
- AMIX N/A
- KLTO N/A
- AVG Volume (30 Days)
- AMIX 13.5K
- KLTO 152.3K
- Earning Date
- AMIX 05-30-2025
- KLTO 05-15-2025
- Dividend Yield
- AMIX N/A
- KLTO N/A
- EPS Growth
- AMIX N/A
- KLTO N/A
- EPS
- AMIX N/A
- KLTO N/A
- Revenue
- AMIX N/A
- KLTO N/A
- Revenue This Year
- AMIX N/A
- KLTO N/A
- Revenue Next Year
- AMIX N/A
- KLTO N/A
- P/E Ratio
- AMIX N/A
- KLTO N/A
- Revenue Growth
- AMIX N/A
- KLTO N/A
- 52 Week Low
- AMIX $1.52
- KLTO $0.11
- 52 Week High
- AMIX $75.80
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- AMIX 53.21
- KLTO N/A
- Support Level
- AMIX $1.61
- KLTO N/A
- Resistance Level
- AMIX $2.06
- KLTO N/A
- Average True Range (ATR)
- AMIX 0.11
- KLTO 0.00
- MACD
- AMIX 0.07
- KLTO 0.00
- Stochastic Oscillator
- AMIX 82.59
- KLTO 0.00
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.